Thus, the management of metastatic disease highly depends on targeted therapies, such as anti-vascular endothelial growth factor (VEGF) antibodies, VEGF receptor tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) pathways inhibitors and immune checkpoint inhibitors [6]. The gene discussed is VEGFA; the disease is metastatic neoplasm.